CHANGES IN HEMATOLOGICAL INDICATORS IN PATIENTS WITH CORONAVIRUS DISEASE

Voronkova O. S., Pavlova O. O., Starishko O. M., Prykhodko O. M., Narbiekova A. V., Simonova O. M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The emergence of a new coronavirus, known as SARS CoV-2, has created an unprecedented challenge for the global medical community. High infection rate, the ability to transmit even during the asymptomatic phase and relatively low virulence led to the rapid spread of the virus in all geographic regions of the world. The purpose of the research was to investigate the significance of clinical analysis indicators in the treatment of patients with COVID-19 and establish their prognostic value. The research was conducted in the medical laboratory of the communal non-profit enterprise “Pavlohrad Hospital of Intensive Treatment” of the Pavlohrad City Council. Hematological indicators were studied using the MicroCC-20Plus automatic hematological analyzer (HTI, USA). The impedance method was used to classify blood cells and determine their levels, and the colorimetric method was used to determine the hemoglobin level. This modern technique allows simultaneous determination of more than 15 indicators, which makes the method complex and allows obtaining a significant amount of information as quickly as possible. Recorded changes in the general blood test, especially in the perspective of assessing the prognosis and degree of severity of the course of the disease in patients suffering from the coronavirus disease. According to the results of research, we learned that men and women over 46 years of age are the main risk groups of COVID-19. Hematological markers of the severity of the condition are simultaneous decrease in the number of erythrocytes and hemoglobin, a decrease in ESR, simultaneous leukocytosis and lymphopenia, as well as monocytopenia in people over 65 years old. A positive prognostic marker of the recovery is an increase in the number of erythrocytes and hemoglobin. Determining the number of individual elements in the indicators of the general blood analysis in dynamics and their ratios can help the clinician in predicative and preventive treatment of patients. General blood analysis, as a convenient and effective tool in clinical practice, is able to provide complete information on hematological parameters that can be used to assess the severity of the disease, monitor the treatment process and the risk of mortality. The results of the study can be applied in monitoring the condition of patients with COVID-19 to assess the severity of the condition and predict recovery.

COVID-19,hematological markers,erythrocytes,hemoglobin,leukocytosis

1. Zozulia IS, Mardzvik VM, Mardzvik MV. Sudynni nevrolohichni uskladnennia u patsiientiv z COVID-19. Ukrainskyi medychnyi chasopys. 2021;ІІІ/IV(142):11-15. DOI: 32471/umj.1680-3051.142.204731. [in Ukrainian].
2. MOZ Ukrainy. «Zhyva» klinichna nastanova. Klinichne vedennia patsiientiv z COVID-19 [Internet]. Kyiv: MOZ Ukrainy; 2022. Dostupno: https://www.dec.gov.ua/mtd/koronavirusna-hvoroba-2019-covid-19/. [in Ukrainian].
3. Melnyk O. COVID-19 ta suputni zakhvoriuvannia. Laboratorna sprava. Spetsializovana vydannia. 2020;8(17):10-20. [in Ukrainian].
4. Chavda VP, Kapadia C, Soni S. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. 2022 Feb 21;14(5):351-371. DOI: 2217/imt-2021-0168.
5. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J. Clin. Investig. 2020 May 1;130(5):2620-2629. DOI: 1172/JCI137244.
6. Chauhan N, Soni S, Jain U. Optimizing testing regimes for the detection of COVID-19 in children and older adults. Expert review of molecular diagnostics. 2021;21(10):999-1016. DOI: 1080/14737159.2021.1962708.
7. Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G, et al. Cochrane COVID-19 Diagnostic Test Accuracy Group (2022). Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews. 2022 Nov 17;11(11):13-15. DOI: 1002/14651858.CD013652.pub2.
8. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik FJ. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Rev Clin Pharmacol. 2021 May 3;14(5):601-621. DOI: 1080/17512433.2021.1902303.
9. Spini A, Giudice V, Brancaleone V, Grazia MM, Francia DS, Filippelli A, et al. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacological Research. 2021 Nov;173:105848. DOI: 1016/j.phrs.2021.105848.
10. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Camargo C, Nikpour B, Armanfard N, et al. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clinical Microbiology Reviews. 2021 May 12:34(3):202. DOI: 1128/ CMR.00228-20.
11. Sharma A, Farouk IA, Kumar SL. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021 Jan 29;13(2):202. DOI: 3390/v13020202.
12. da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, et al. Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infect Dis. 2022 Jul 15;8(9):1758-1814. DOI: 1021/acsinfecdis.2c00204.
13. Zhang J, Huang X, Tao Z. Correlation of clinical characteristics between patients with seasonal influenza and patients infected by the wild type or delta variant of SARS-CoV-2. Front Public Health. 2022 Aug 18;10:981233. DOI: 3389/fpubh.2022.981233.
14. Hanssen JLJ, Stienstra J, Boers SA, Pothast CR, Zaaijer HZ, Tjon JM, et al. Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity. Infect Dis Rep. 2021 Sep 27;13(4):855-864. DOI: 3390/idr13040077.
15. Salimi-Jeda A, Abbassi S, Mousavizadeh A. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology. 2021 Dec;101(Pt A):108232. DOI: 1016/j. intimp.2021.108232.
16. Dinnes J, Sharma P, Berhane S, Wyk SS, Nyaaba N, Domen J, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. The Cochrane database of systematic reviews. 2022 Jul 22;7(7):CD013705. DOI: 1002/14651858.CD013705.pub3.
17. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities M.R. Clin Chim Acta. 2020 May 29;508:254-266. DOI: 1016/j.cca.2020.05.044.
18. Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. International Immunopharmacology. 2020 Nov;88:106924. DOI: 1016/J.intimp.2020.106924.
19. Pozdnyakova O, Connell NT, Battinelli EM, Connors JM, Fell G, Kim AS, Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. American Journal of Clinical Pathology. 2021;155(3):364-375. DOI: 1093/ajcp/ aqaa231.
20. Al-Ansari RY, Abdalla LM, Qomawi YA, Alromaih LJ, Bakkar M, Shilash AS, et al. Coronavirus disease 2019 (COVID-19) in special groups: A single-center experience in sickle cell disease patients in Saudi Arabia . J Family Community Med. 2022;29(1):71-78. DOI: 4103/ jfcm.jfcm_376_21.
21. Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020 May 30;98(1):14. DOI: 1016/j.diagmicrobio.2020. 115094.
22. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Singh YM, et al. Coronavirus Disease 2019-COVID-19. Clinical microbiology reviews. 2020 Jun 24;33(4):e00028-20. DOI: 1128/CMR.00028-20.
23. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343-360. DOI:10.1631/jzus. B2000083.
24. Seyit M, Avci E, Nar R, Senol H, Yilmaz A, Ozen M, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. The American journal of emergency medicine. 2021 Dec 31;40:110-114. DOI:10.1016/j.ajem.2020. 11.058.

«Bulletin of problems biology and medicine» Issue 1 (168), 2023 year, 120-130 pages, index UDK 616-098

10.29254/2077-4214-2023-1-168-120-130